VANCOUVER, BC--(Marketwire - May 12, 2010) - Stellar Biotechnologies, Inc. (TSX-V: KLH) has appointed Dr. Andrew Saxon, a world-renowned expert in human cellular and molecular immunology, Andrew Saxon, M.D., Chairman - SAB. Dr. Saxon is Professor & Chief Emeritus, Clinical Immunology/Allergy in the Department of Medicine, David Geffen School of Medicine at UCLA.
CEO Frank Oakes said, “It is Stellar’s great fortune to have a physician and research scientist like Dr. Saxon heading up and developing an active Scientific Advisory Board. He is one of the key figures leading the drive to develop a commercial primary human immune response diagnostic based on our important product, KLH (http://en.wikipedia.org/wiki/Keyhole_limpet_hemocyanin). He has also identified leading candidates in protein engineering, therapeutic vaccine and molecular diagnostic development and novel therapeutics to fill out the SAB.”
Dr. Saxon received his medical degree from Harvard Medical School. He has published over 180 peer reviewed research papers primarily dealing with the control and assessment of the human immune response. Dr. Saxon and colleagues at UCLA were the first to recognize AIDS in 1980, brought it to the attention of the CDC in 1981, and published the first research describing it in the New England Journal of Medicine. Dr. Saxon has had extensive experience with KLH in its various molecular forms. He is Editor-in-Chief of Clinical Immunology, the official journal of the Clinical Immunology Society.
Dr. Saxon said, “I’m really pleased to be able to contribute to the growth of this truly exciting and dynamic company. Stellar Biotechnologies is sitting at the nexus of a new era of therapies and diagnostics driven by what I believe will be ever growing use of its key product, KLH, a potent, yet safe, molecule that can be used to both drive the immune system as well as assess the immune systems functional status. Because of the unique properties of KLH, an expanding number of researchers and scientists in academia, biotech and Pharma are finding novel and amazing uses for it. I believe an active SAB can enhance growth as well as help direct the board and executives to new markets and expanded use of this rare, naturally-sourced molecule and important medical reagent.”
www.StellarBiotechnologies.com
About Stellar Biotechnologies, Inc. (TSX-V: KLH): Stellar’s product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is being used in medicines known as conjugate therapeutic vaccines and in other biomedical products. Already a world leader in the production of KLH, Stellar plans to further monetize its KLH production platform and maximize the commercial impact of its intellectual property portfolio through the physical sourcing, purification and supply of medical-grade KLH.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Darrell Brookstein
VP
dbrookstein@stellarbiotech.com
